High-Parameter Mass Cytometry (CyTOF) Evaluation of Relapsed/Refractory Multiple Myeloma (MM) Pts (Pts) Treated with Daratumumab Supports Immune Modulation As a Novel Mechanism of Action

被引：6

作者：

Adams, Homer, III ^{[1
]}

Stevenaert, Frederik ^{[2
]}

Krejcik, Jakub ^{[3
,4
,5
]}

Van der Borght, Koen ^{[2
]}

Casneuf, Tineke ^{[2
]}

Smets, Tina ^{[2
]}

Bald, Jaime ^{[1
]}

Abraham, Yann ^{[2
]}

Ceulemans, Hugo ^{[2
]}

Vanhoof, Greet ^{[2
]}

Ahmadi, Tahamtan ^{[1
]}

Usmani, Saad Z. ^{[6
]}

Plesner, Torben ^{[7
,8
]}

Lonial, Sagar ^{[9
]}

van Kessel-Welmers, Berris ^{[10
]}

Lokhorst, Henk M. ^{[10
]}

Mutis, Tuna ^{[10
]}

van de Donk, Niels W. C. J. ^{[10
]}

Sasser, A. Kate ^{[1
]}

机构：

[1] Janssen Res & Dev LLC, Spring House, PA USA

[2] Janssen Res & Dev, Beerse, Belgium

[3] Vejle Hosp, Vejle, Denmark

[4] Univ Southern Denmark, Vejle, Denmark

[5] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

[6] Levine Canc Inst, Carolinas Healthcare Syst, Charlotte, NC USA

[7] Vejle Hosp, Dept Hematol, Vejle, Denmark

[8] Univ Southern Denmark, Dept Hematol, Vejle, Denmark

[9] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[10] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.4521.4521

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

4521

引用

页数：7

共 16 条

[1] High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
Adams, Homer C., III
Stevenaert, Frederik
Krejcik, Jakub
Van der Borght, Koen
Smets, Tina
Bald, Jaime
Abraham, Yann
Ceulemans, Hugo
Chiu, Christopher
Vanhoof, Greet
Usmani, Saad Z.
Plesner, Torben
Lonial, Sagar
Nijhof, Inger
Lokhorst, Henk M.
Mutis, Tuna
van de Donk, Niels W. C. J.
Sasser, Amy Kate
Casneuf, Tineke
[J]. CYTOMETRY PART A, 2019, 95A (03) : 279 - 289
[2] Daratumumab-induced in vivo immune modulation in relapsed and/refractory multiple myeloma patients treated with daratumumab-len-dex
Giannotta, Claudia
Ziccheddu, Bachisio
D'Agostino, Mattia
Bertuglia, Giuseppe
Saraci, Elona
Oliva, Stefania
Bolli, Niccolo'
Landgren, Ola
Bruno, Benedetto
Boccadoro, Mario
Maura, Francesco
Massaia, Massimo
Larocca, Alessandra
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S256 - S257
[3] New therapies for relapsed/refractory multiple myeloma (RRMM) patients (pts) with novel mechanisms of action (CELMODs, Selinexor, Belantamab Mafodotin and beyond)
Engelhardt, M.
Rassner, M.
Jung, J.
Waldschmidt, J.
Moeller, M.
Greil, C.
Miething, C.
Waesch, R.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 14 - 14
[4] Daratumumab (DARA) in combination with carfilzomib and dexamethasone (D-Kd) in lenalidomide (Len)-refractory patients (Pts) with relapsed multiple myeloma (MM): Subgroup analysis of MMY1001.
Chari, Ajai
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Blade, Joan
Lonial, Sagar
Benboubker, Lotfi
Oriol Rocafiguera, Albert
Arnulf, Bertrand
San-Miguel, Jesus
Pineiro, Luis
Jakubowiak, Andrzej J.
De Boer, Carla
Wang, Jianping
Schecter, Jordan Mark
Moreau, Philippe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[5] Biologic and clinical evaluation of high intermittent dose all trans retinoic acid (ATRA) in refractory multiple myeloma (MM) patients (PTS).
Hussein, MA
Bocock, K
Bloom, T
Finke, J
Rybicki, L
Scott, R
Bukowski, RM
[J]. BLOOD, 1998, 92 (10) : 108A - 109A
[6] Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial
Richardson, Paul G.
Sandhu, Irwindeep
Hofmeister, Craig C.
Orlowski, Robert Z.
White, Darrell
Belotti, Angelo
Hansen, Charlotte Toftmann
Raje, Noopur S.
Chow, Tracy T.
Zhou, Zehua
Civardi, Tiziana
Koo, Phillip
Zhu, Yue
Katz, Jessica
Oriol, Albert
[J]. BLOOD, 2023, 142
[7] Immune Profile of Patients (pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM) Treated with Pomalidomide (POM) plus Low-Dose Dexamethasone (LoDEX) plus Daratumumab (DARA) in the Second Line Immediately after Lenalidomide (LEN)
Qian, Xiaozhong
Newhall, Kathryn
Tometsko, Mark
Bjorklund, Chad
Ma, Jianglin
Bahlis, Nizar J.
Siegel, David
Schiller, Gary J.
Samaras, Christy
Sebag, Michael
Berdeja, Jesus G.
Ganguly, Siddhartha
Matous, Jeffrey V.
Song, Kevin W.
Seet, Christopher S.
Talamo, Giampaolo
Srinivas, Shanthi
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Mouro, Jorge
Agarwal, Amit
Zafar, Faiza
Thakurta, Anjan
[J]. BLOOD, 2017, 130
[8] The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice
Leleu, Xavier
Boccadoro, Mario
Lee, Hans C.
Zonder, Jeffrey A.
Macro, Magaret
Ramasamy, Karthik
Hulin, Cyrille
Silar, Jiri
Kuhn, Matyas
Ren, Kaili
Bent-Ennakhil, Nawal
Bouillie, Sylvie
Cherepanov, Dasha
Stull, Dawn Marie
Terpos, Evangelos
[J]. BLOOD, 2021, 138
[9] Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor
Avet-Loiseau, Herve
San-Miguel, Jesus F.
Casneuf, Tineke
Iida, Shinsuke
Lonial, Sagar
Usmani, Saad Z.
Spencer, Andrew
Moreau, Philippe
Plesner, Torben
Weisel, Katja
Ukropec, Jon
Okonkwo, Linda
Trivedi, Sonali
Velas, Christopher Joseph
Qin, Xiang
Qi, Ming
Chiu, Christopher
Bahlis, Nizar
[J]. BLOOD, 2018, 132
[10] Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM)
Berenson, James R.
Hilger, James D.
Dichmann, Robert
Patel-Donnelly, Dipti
Boccia, Ralph V.
Bessudo, Alberto
Stampleman, Laura
Gravenor, Donald
Eshaghian, Shahrooz
Chamras, Hilda
Nassir, Youram
Swift, Regina A.
Vescio, Robert A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 →